Aaron Davis

Tavistock Life Sciences Co (Tavistock Life Sciences Co.) is a venture capital firm founded in 2002. The firm is headquartered in San Diego, California.

Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA.

BCTG Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in May 2020 and is headquartered in San Diego, CA.

Part of Tavistock Group, Inc., MVA Investors LLC is a company that provides investment services. The company is based in San Diego, CA. The CEO of the company is Aaron I. Davis.

CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA.

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.

Part of Tavistock Group, Inc., the company is based in Windermere, FL. Tavistock Group, Inc. (United States) is an international private investment family office that invests in various sectors such as real estate, hotels, restaurants, sports, energy, retail, biotechnology, agriculture, and finance. The company brings capital, experience, flexibility, and a broad base to their investments. The company was founded on the philosophy of striving for excellence in everything they do and values long-term relationships with their investments around the world.

Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.